Catalent Biologics Expands Into ADCs - - BioPharm International

ADVERTISEMENT

Catalent Biologics Expands Into ADCs


Catalent Pharma Solutions announced in a statement that it has acquired an exclusive license to market Redwood Bioscience’s proprietary SMARTag precision protein-chemical engineering technology for the development of advanced antibody-drug conjugates (ADCs). 

Redwood’s novel, site-specific protein modification and linker technologies enable the generation of homogenous bioconjugates engineered to enhance potency, safety, and stability.  Catalent offers a proprietary GPEx cell line expression system, a biomanufacturing Center of Excellence in Madison, Wis., and range of bioanalytical and fill-finish services.

ADCs combine the targeted binding specificity and half-life benefits of monoclonal antibodies with the potency advantages of small molecule chemotherapy or therapeutic agents. With the FDA’s recent approval of Genentech’s T-DM1 (Kadcycla™) for metastatic breast cancer, and a large and growing list of products in clinical and pre-clinical development, ADCs are emerging as one of the fastest growing development areas in biologic anti-cancer treatment, according to the statement.

Under the terms of the agreement, Catalent will have the exclusive right to sub-license the SMARTag technology to customers and will work with Redwood to co-market the technology and support sub-license programs. Catalent will also take a minority equity stake in Redwood, which may increase over time up to a potential acquisition.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines

Click here